HTG to host a free scientific webinar on immunotherapy outcomes for patients suffering from head and neck, and lung cancers

On November 4, 2022 HTG will host another event in their webinar series  featuring Dr. Pierre Saintigny, Professor of Medicine at University Claude Bernard Lyon 1 and medical oncologist at the Léon Bérard Cancer Center (CLB). The webinar is titled "Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients".  Registration is free and an on-demand replay will be made available after the event for registrants who were unable to join live.

Prof. Saintigny leads the translational research team “Integrated Analysis of the Dynamics of Cancer” and co-directs the Department Tumor Escape Resistance and Immunity at the Cancer Research Center of Lyon. He is focusing most of his research in head and neck disease from preneoplasia to established squamous cell carcinoma (SCC), before and under the selective pressure of systemic therapy. His scientific objective is to understand the longitudinal dynamics of SCCHN to develop clinically relevant preventive and treatment strategies at specific time points of the natural history. His team integrates clinical, pathological and molecular profiles to unravel the dynamic changes during early stages of tumorigenesis and under the selective pressure of therapy, to reveal vulnerabilities that may in turn translate into new treatment and prevention strategies.


The key learning objectives of the webinar include:

  • Gain insight into recent advances in RNA-based gene expression profiling
  • Identify opportunities to improve outcomes for patients suffering from HNSCC and NSCLC under immunotherapy
  • Review the utility of ultra-efficient GEP in real-world applications, such as oncological research
  • Understand the benefits of novel profiling technologies compared to traditional methods
Posted on:

Return To List

Page last updated October 14, 2022